


Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name _____

Attorney Docket Number 38005-0126

RECEIVED

JUN 29 2001

~~TECH CENTER 1600/2900~~

Shee

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A46	A Rapidly Activating and Slowly Inactivating Potassium Channel Cloned from Human Heart, Functional Analysis after Stable Mammalian Cell Culture Express, Dirk J. Snyders, Michael M. Tamkun, Paul B. Bennett, Vanderbilt Univ. School of Medicine, Nashville, TN, J. Gen. Physiol. The Rockefeller University Press 0022-1295/943/04/0513/31, Vol. 101, pp. 513-543, April 1993	


Examiner Signature	Walter S. M.	Date Considered	4/29/02
--------------------	--------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



FD-1079A47-13
PTO/SB/06A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of 1

TRADEMARKS

TRADEMARKS

Complete if Known

Application Number	09/758,036
Filing Date	January 11, 2001
First Named Inventor	LEBERER, Ekkehard
Group Art Unit	1645-1636
Examiner Name	Unassigned
Attorney Docket Number	38005-0126

Sheet 1 of 1 Attorney Docket Number 38005-0126

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	TECH CENTER 1600/2900
G	A47	GABER, R. F. et al., "TRK1 Encodes a Plasma Membrane Protein Required for High-Affinity Potassium Transport in <i>Saccharomyces cerevisiae</i> ", Molecular and Cellular Biology, July 1988, pp. 2848-2859, Vol. 8, No. 7.	
G	A48	GÜLDENER, U. et al., "A new efficient gene disruption cassette for repeated use in budding yeast", Nucleic Acids Research, 1996, pp. 2519-2524, Vol. 24, No. 13, Oxford University Press.	
G	A49	RICHELSON, E., "Preclinical Pharmacology of Neuroleptics: Focus on New Generation Compounds", J Clin Psychiatry, 1996, pp. 4-11, Vol. 57, Suppl 11.	
B	A50	SANGUINETTI, M. C. et al., "Molecular physiology of cardiac delayed rectifier K ⁺ channels", Heart Vessels, 1997, pp. 170-172, Suppl. 12, Springer-Verlag.	
B	A51	YAMADA, M. et al., "G Protein Regulation of Potassium Ion Channels", Pharmacological Reviews, 1998, pp. 723-757, Vol. 50, No. 4.	
D	A52	DRICI, M. D. et al., "Cardiac K ⁺ channels and drug-acquired long QT syndrome", Thérapie, 2000, pp. 185-193, Vol. 55.	

Examiner Signature

with an attachment

Date Considered

4/29/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TRADEMARKS



26633

U.S. PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 17 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number 09/758,036

Filing Date January 11, 2001

First Named Inventor Ekkehard LEBERER, et al.

Group Art Unit 1645

Examiner Name Unassigned

Attorney Docket Number 38005-0126

Sheet 2 of 2

ANSWER

Introducing the new [Windows 8](#) | [Windows 8.1](#)

AUG 28 2001

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner
Signature

(N.Y. in sample)

Date
Considered

4/29/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.